Meta-analysis: A randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 9, 2004, Pages 931-938

  Khuroo, Mohammad S ^a,c   Khuroo, Mehnaaz S ^b   Dahab, Salim T ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b SRI RAMACHANDRA UNIVERSITY   (India)

^c MBC 46 ^*  (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ACCURACY; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COMPARATIVE STUDY; DATA ANALYSIS; DOSE RESPONSE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CIRRHOSIS; META ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 9944257515     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02208.x     Document Type: Article

References (28)

1. Lauer GM, Walker BD. Hepatitis C virus infection. New Engl J Med 2001; 345: 41-52.
2. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (Suppl.): 35-46.
3. Craxi A, Licata A. Clinical trial results of peginterferons in combination with ribavirin. Semin Liver Dis 2003; 23 (Suppl. 1): 35-46.
4. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370-81.
5. Simmonds P. Viral heterogeneity of hepatitis C virus. J Hepatol 1999; 31 (Suppl.): 54-60.
6. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominga T, Persing DH. Hepatitis C genotypes in the United States: epidemiology, pathogenesis, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 1996; 125: 634-9.
7. Shobokshi OA, Serebour FE, Skakni L, Al-Saffy YH, Ahdal MN. Hepatitis C genotypes and subtypes in Saudi Arabia. J Med Virol 1999; 58: 44-8.
8. Keefe EB. Peginterferons in hepatitis C virus: virological, pharmacokinetic, and clinical implications. Semin Liver Dis 2003; 23 (Suppl 1): 1-2.
9. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.
10. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
11. National Institutes of Health. NIH Consensus Development Conference Statement. Proceedings of the Management of Hepatitis C; 2002, June 10-12; Bethesda MD. Gastroenterology 2002; 123: 2082-99.
12. Moher D, Cook DJ, Eastwood S, Olkin I, Rennei D, Stroup DF. Improving the quality of reports of meta-analysis of randomized controlled trials: the QUORUM statement. Lancet 1999; 354: 1896-900.
13. Petitti DB. Meta-analysis, Decision Analysis, and Cost-effectiveness Analysis, 2nd edn. New York: Oxford University Press, 2000.
14. Juni P, Witschi A, Bloch R, Egger M. The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 1999; 282: 1054-60.
15. Der Simonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
16. Egger M, Davey SG, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
17. Cucherat M, Boissel JP, Leizorovicz A. EasyMA: a program for the meta-analysis of clinical trials. Comput Methods Programs Biomed 1997; 53: 187-90.
18. Esmat G, Abouzied AM, Adel-Aziz F, Strickland T. Subjects with chronic hepatitis C and genotype 4 have a similarly effective response to standard or pegylated interferon in combination with ribavirin. Hepatology 2003; 38: 324A.
19. Shobokshi OA, Serebour FE, Skakni L, Al Khalifa M. Combination therapy of peginterferon alfa-2a and ribavirin significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia. Hepatology 2003; 38: 996A.
20. Thakeb FAI, Omar MM, El Awady MM, Isshak SY. Randomized controlled trial of peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus genotype 4 among Egyptian patients. Abstract 37, Proceedings of the 54th Annual Meeting of the AASLD, Boston, MA, October 24-28, 2003.
21. Faleh FZ, Hadad Q, Khuroo MS, et al. Peginterferon alfa-2b plus ribavirin compared to Interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4. Proceedings of the Emirates Pan-Arab Gastroenterology Week, Sharjah, UAE, January 13-17, 2004.
22. Castera L, Morice Y, Grando V, Bon C, Deny P, Roulot L. Le virus de l'hépatite C de génotype4. caractéristiques épidémiologiques et résponse aux traitements antiviraux. Gastroenterol Clin Biol 2003; 27: 596-604.
23. Neumann AU, Lam NP, Dahari H, et al. Differences in viral dynamics between genotype 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35.
24. Pawlotsky J-M, Hezode C, Pellegrin B, et al. Early HCV genotype 4 replication kinetics during treatment with peginterferon alfa-2a (Pegasys)-ribavirin combination. A comparison with HCV genotype 1 and 3 kinetics. Hepatology 2002; 36: 291A.
25. Ferenci P. Weight-based dosing of pegylated interferon alfa in chronic hepatitis C-Just a marketing 'gag'? Dig Liver Dis 2003; 35: 601-6.
26. Hassan F, Asker H, Al-Khaldi J, et al. Pegylated interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis genotype 4. Hepatology 2003; 38: 982A.
27. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C. A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
28. Diago M, Hassanein T, Rodes J, Ackrill AM, Sedarati F. Optimized virological response in hepatitis C virus genotype 4 with peginterferon alfa-2a and ribavirin (letter). Ann Intern Med 2004; 140: 72-3.